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Abstract
Introduction: Primary lymphoma of the prostate is very rare. In this paper we present a case of
early stage non-Hodgkin lymphoma of the prostate managed with six cycles of rituximab-based
chemotherapy, and review the related literature.
Case presentation: An 84-year-old man was admitted to our hospital having signs and symptoms
suggestive of prostatic disease for 3 years. Histological and immunocytochemical studies of trans-
urethral biopsy of the prostate showed diffuse large B-cell lymphoma. Radiological assessment of
disease confirmed the diagnosis of early stage lymphoma of the prostate. The patient was managed by
6 of rituximab 375 mg/m² on day 1, cyclophosphamide 750 mg/m² on day 1, doxorubicin 50 mg/m² on
day 1, vincristine 1.4 mg/m² on day 1, and prednisone 50 mg/m² on days 1 to 5 with complete clinical
and radiological response. He remained disease free, until now, 30 months after the end of
chemotherapy.
Conclusion: According to the literature, the treatment and prognosis of primary lymphoma of the
prostate is the same as that of other nodal lymphomas. Rituximab-based regimen should be
considered in the management of prostatic diffuse large B-cell lymphoma.
Introduction
Primary lymphoma of the prostate is extremely rare
representing approximately 0.2 to 0.8% of extra nodal
lymphoma and 0.1% of all prostate neoplasms [1-3]. In
this paper, we present a case of prostatic early large B-cell
lymphoma of an 84-year-old man managed successfully
with rituximab-based chemotherapy and review of the
related literature.
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An 84-year-old Moroccan Caucasian man admitted in our
institution with difficulty of urination, suggestive of
urinary obstruction for 3 years and having systemic
symptoms (B symptoms) (Fever, shudder, profuse sweat,
without weigh loss) for 6 months. He had no relevant past
medical history. At first diagnosis, the performance status
was equal to 1.0. Digital rectal examination showed firm
prostate weighing 30 g. Ultrasound prostate and kidneys
examination showed voluminous prostate (35 g) and
bilateral hydronephrosis. The serum tumour marker
serum Prostate-specific antigen (PSA) was negative,
being 2.97 ng/ml (normal <4 ng/ml).
Histological and immunohistochemical studies of needle
biopsies of prostatic tissue obtained by transurethral
resection showed diffuse large B-cell lymphoma
(DLBCL). Most of the neoplastic cells were positive for
Cluster of differentiation-20 (CD-20) and leukocyte
common antigen (LCA).
Computed tomography (CT) scanand magnetic resonance
imaging (MRI) of the pelvis showed a large prostatic
tumour (Figure 1). The tumour invaded the base of the
bladder (Figure 2 and Figure 3). No evidence of distant
metastasis on lung and abdomen was shown by CT scan.
The erythrocyte sedimentation rate was increased, being
65 mm inthe first hour. Abone marrowbiopsy showed no
abnormalities. The patient was staged IEBb according to
the Ann Arbor classification system. He was managed with
six cycles of rituximab 375 mg/m² on day 1, cyclophos-
phamide 750 mg/m² on day 1, doxorubicin 50 mg/m² on
day 1, vincristine 1.4 mg/m² on day 1, and prednisone
50 mg/m² on day 1 to 5 (RCHOP regimen). The evaluation
was done by abdomino-pelvic and chest CT scans. The first
CT scan of the pelvis performed after 3 cycles of
chemotherapy showed partial radiological response of the
prostatic tumour and the second (Figure 4) performed after
the end of the 6 cycles of treatment showed complete
radiological response. The patient remained disease free,
until now, 30 months after the end of the chemotherapy.
Figure 1. CT scan of the pelvis shows the tumoral process
infiltrated the base of the prostate gland.
Figure 2. T2 weighted coronal section fat-suppressed shows
the process in the left base of the prostate which invades the
bladder base.
Figure 3. T1 weighted coronal section after injection of
gadolinium shows abnormal enhancement of the prostate and
the bladder base.
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Adenocarcinoma represents more than 90% of all
prostatic malignancies. Other histological subtypes of
prostatic cancers represent only 5 to 10%. Involvement of
the prostate by malignant lymphoma is a well-known late
manifestation of advanced nodal disease [4]. However,
primary lymphoma of the prostate is extremely rare
representing only 0.2 to 0.8% of extra nodal lymphoma
and 0.1% of all prostate neoplasms [1-3]. It is estimated
that less than 150 cases have been described in the world
literature.
The mean age at diagnosis is 62 years [5]. The criteria for
the diagnosis of primary prostatic lymphoma were defined
by Bostwick et al. [5]. Tumours were considered to be
primary for patients having the following: (1) symptoms
of prostatic enlargement at the beginning of the disease;
(2) predominant involvement of prostate; and (3) no
involvement of lymph nodes, blood, liver, or spleen [5].
Almost all patients diagnosed with prostatic lymphoma,
whether primary or secondary, present symptoms of lower
urinary obstruction [2,3,5]. Some patients present pain or
hematuria, and others present systemic symptoms. PSA is
increased for 20% of alls cases. On digital rectal examina-
tion the prostate appears diffusely enlarged or nodular,
and firm [6]. For our patient, we showed urinary
obstruction, systemic symptoms and firm prostate weigh-
ing 30 g on digital rectal examination.
Pathological diagnosis is usually obtained by examination
of needle biopsies of prostatic tissue obtained by
transurethral resection. Occasionally lymphoma is diag-
nosed as an incidental finding in a radical prostatectomy
specimen removed for known prostatic adenocarcinoma
[6]. We may also encounter lymphoma/leukemia as an
incidental finding in approximately 0.2 to 1.2% of
pelvic lymph node resections performed at radical
prostatectomy [7,8].
T h eD L B C Li st h em o s tc o m m o nt y p eo fp r i m a r y
lymphomas of the prostate, but primary prostatic small
lymphocytic lymphoma, follicular lymphomas, Burkit
lymphomas, MALT lymphomas, and mantle cell lympho-
mas have also been reported [2,3,5,9].
Because primary lymphoma of the prostate is rare, little is
known of its optimal management. In the retrospective
review of 62 patient performed by Bostwick et al. [5], 47%
of patients died of lymphoma, the specific 5-year survival
was only 33%. 73% of patients with primary prostatic
lymphoma developed extra prostatic disease 1 to
59 months after diagnosis. There were no significant
differences in survival between patients receiving different
therapies: chemotherapy, chemotherapy and radiotherapy
or surgery only. There were no significant differences
between patients with primary or secondary prostatic
lymphoma, or between patients with different types of
lymphoma [5]. However, patients in this retrospective
study concern cases found in different centres during
58-year period, and it is unlikely that these data reflect the
results that would be achieved using current therapeutic
regimens. Indeed, a number of more recent case studies
have reported good outcomes for patients with high-grade
primary prostatic lymphoma treated with anthracycline-
based chemotherapy with or without radiotherapy
[2,10,11]. Other cases with localised diffuse large B-cell
lymphoma were managed successfully with radiotherapy
only [12]. Rituximab in combination with CHOP regimen
is considered as the standard treatment for patients with
advanced stage DLBCL [13]. Studies of rituximab use in
the management of gastrointestinal and other extra-nodal
lymphoma are ongoing in research programs. And the first
results appear to be encouraging. To our knowledge, the
present case is the first case of early primary lymphoma of
the prostate which was managed successfully with RCHOP
chemotherapy.
Because of the rarity of the disease, the prognosis of
primary prostatic lymphoma is not clear. It remains
uncertain whether the prognosis of prostatic lymphoma
is significantly worse or equivalent to nodal lymphoma. In
one review of 23 cases of Japanese primary prostatic
lymphoma the authors suggest that patients with this
malignancy respond well to chemotherapy and could
possibly be cured when the disease is confined to prostatic
region [14]. Others authors suggest that prognosis of these
malignancies dependent on the histological type and stage
of the individual tumour, as it is the case of other non-
Hodgkin’s lymphomas [12]. In concordance with theses
conclusions, the prognosis and treatment of other extra
Figure 4. CT scan of the pelvis performed after
chemotherapy shows complete radiological response of the
prostatic tumour.
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Conclusion
Primary lymphoma of the prostate is rare. In most cases
the diagnosis was induced by urinary obstruction. Because
of the rarity of disease, there is no standard treatment,
universally accepted of primary DLBCL of the prostate.
For early stage, the combination of chemotherapy and
radiotherapy appears to be a logical option. For advanced
disease, rituximab in association with CHOP chemo-
therapy should be considered as the first-choice treatment.
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